Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | UBE2N | P61088 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1131967 | 0.78 | — | — | |
| SCHEMBL5517670 | 0.77 | — | — | |
| SCHEMBL1132477 | 0.77 | — | — | |
| SCHEMBL5234419 | 0.77 | — | — | |
| SCHEMBL15209529 | 0.77 | — | — | |
| SCHEMBL15209859 | 0.77 | — | — | |
| SCHEMBL143927 | 0.75 | — | — | |
| SCHEMBL10889704 | 0.75 | — | — | |
| SCHEMBL143928 | 0.75 | — | — | |
| SCHEMBL607966 | 0.75 | ANPEP (0.52) | TDP1TSHRCYP2D6LMNAGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240894-A1 | METHOD FOR PRODUCING AMINES FROM GLYCERIN | BASF SE (DE) | 2010-09-23 | — | — | US | disclosed |
| EP-2185499-A1 | METHOD FOR PRODUCING AMINES FROM GLYCERIN | BASF SE (DE) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009027248-A1 | METHOD FOR PRODUCING AMINES FROM GLYCERIN | BASF SE (DE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240894-A1 | METHOD FOR PRODUCING AMINES FROM GLYCERIN | GNMT, GK, GMPS | TRPV1 1268/4885TRPA1 847/4885TDP1 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.